Ramatroban

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ramatroban
Accession Number
DB13036
Type
Small Molecule
Groups
Investigational
Description

Ramatroban has been used in trials studying the treatment of Asthma.

Structure
Thumb
Synonyms
Not Available
Categories
UNII
P1ALI72U6C
CAS number
116649-85-5
Weight
Average: 416.47
Monoisotopic: 416.120606501
Chemical Formula
C21H21FN2O4S
InChI Key
LDXDSHIEDAPSSA-OAHLLOKOSA-N
InChI
InChI=1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
IUPAC Name
3-[(3R)-3-(4-fluorobenzenesulfonamido)-2,3,4,9-tetrahydro-1H-carbazol-9-yl]propanoic acid
SMILES
[H][C@]1(CCC2=C(C1)C1=CC=CC=C1N2CCC(O)=O)NS(=O)(=O)C1=CC=C(F)C=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UProstaglandin D2 receptor 2Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe risk or severity of bleeding can be increased when Ramatroban is combined with (R)-warfarin.
(S)-WarfarinThe risk or severity of bleeding can be increased when Ramatroban is combined with (S)-Warfarin.
4-hydroxycoumarinThe risk or severity of bleeding can be increased when Ramatroban is combined with 4-hydroxycoumarin.
AbciximabRamatroban may increase the anticoagulant activities of Abciximab.
AcenocoumarolThe risk or severity of bleeding can be increased when Ramatroban is combined with Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ramatroban is combined with Acetylsalicylic acid.
AlaproclateThe risk or severity of hemorrhage can be increased when Alaproclate is combined with Ramatroban.
AldesleukinThe risk or severity of bleeding can be increased when Ramatroban is combined with Aldesleukin.
AlemtuzumabThe risk or severity of bleeding can be increased when Ramatroban is combined with Alemtuzumab.
AloxiprinThe risk or severity of adverse effects can be increased when Ramatroban is combined with Aloxiprin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
123879
PubChem Substance
347829169
ChemSpider
110413
BindingDB
50161746
ChEBI
32087
ChEMBL
CHEMBL361812
Wikipedia
Ramatroban

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2, 3WithdrawnTreatmentAsthma Bronchial1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0227 mg/mLALOGPS
logP2.3ALOGPS
logP3.3ChemAxon
logS-4.3ALOGPS
pKa (Strongest Acidic)4.39ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area88.4 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity107.08 m3·mol-1ChemAxon
Polarizability42.28 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as carbazoles. These are compounds containing a three ring system containing a pyrrole ring fused on either side to a benzene ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Carbazoles
Direct Parent
Carbazoles
Alternative Parents
3-alkylindoles / Benzenesulfonamides / N-alkylindoles / Benzenesulfonyl compounds / Fluorobenzenes / Substituted pyrroles / Organosulfonamides / Aryl fluorides / Aminosulfonyl compounds / Heteroaromatic compounds
show 9 more
Substituents
Carbazole / Benzenesulfonamide / N-alkylindole / 3-alkylindole / Benzenesulfonyl group / Indole / Fluorobenzene / Halobenzene / Aryl fluoride / Aryl halide
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Sugimoto H, Shichijo M, Okano M, Bacon KB: CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist responses. Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. Epub 2005 Oct 27. [PubMed:16256979]

Drug created on October 20, 2016 20:16 / Updated on November 02, 2018 07:33